335 related articles for article (PubMed ID: 18394554)
1. Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.
Wernig G; Kharas MG; Okabe R; Moore SA; Leeman DS; Cullen DE; Gozo M; McDowell EP; Levine RL; Doukas J; Mak CC; Noronha G; Martin M; Ko YD; Lee BH; Soll RM; Tefferi A; Hood JD; Gilliland DG
Cancer Cell; 2008 Apr; 13(4):311-20. PubMed ID: 18394554
[TBL] [Abstract][Full Text] [Related]
2. Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors.
Geron I; Abrahamsson AE; Barroga CF; Kavalerchik E; Gotlib J; Hood JD; Durocher J; Mak CC; Noronha G; Soll RM; Tefferi A; Kaushansky K; Jamieson CH
Cancer Cell; 2008 Apr; 13(4):321-30. PubMed ID: 18394555
[TBL] [Abstract][Full Text] [Related]
3. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.
Mullally A; Lane SW; Ball B; Megerdichian C; Okabe R; Al-Shahrour F; Paktinat M; Haydu JE; Housman E; Lord AM; Wernig G; Kharas MG; Mercher T; Kutok JL; Gilliland DG; Ebert BL
Cancer Cell; 2010 Jun; 17(6):584-96. PubMed ID: 20541703
[TBL] [Abstract][Full Text] [Related]
4. The JAK kinase inhibitor CP-690,550 suppresses the growth of human polycythemia vera cells carrying the JAK2V617F mutation.
Manshouri T; Quintás-Cardama A; Nussenzveig RH; Gaikwad A; Estrov Z; Prchal J; Cortes JE; Kantarjian HM; Verstovsek S
Cancer Sci; 2008 Jun; 99(6):1265-73. PubMed ID: 18482053
[TBL] [Abstract][Full Text] [Related]
5. Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.
Zaleskas VM; Krause DS; Lazarides K; Patel N; Hu Y; Li S; Van Etten RA
PLoS One; 2006 Dec; 1(1):e18. PubMed ID: 17183644
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth.
Li Z; Xu M; Xing S; Ho WT; Ishii T; Li Q; Fu X; Zhao ZJ
J Biol Chem; 2007 Feb; 282(6):3428-32. PubMed ID: 17178722
[TBL] [Abstract][Full Text] [Related]
7. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
8. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
Quintás-Cardama A; Vaddi K; Liu P; Manshouri T; Li J; Scherle PA; Caulder E; Wen X; Li Y; Waeltz P; Rupar M; Burn T; Lo Y; Kelley J; Covington M; Shepard S; Rodgers JD; Haley P; Kantarjian H; Fridman JS; Verstovsek S
Blood; 2010 Apr; 115(15):3109-17. PubMed ID: 20130243
[TBL] [Abstract][Full Text] [Related]
9. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.
Pikman Y; Lee BH; Mercher T; McDowell E; Ebert BL; Gozo M; Cuker A; Wernig G; Moore S; Galinsky I; DeAngelo DJ; Clark JJ; Lee SJ; Golub TR; Wadleigh M; Gilliland DG; Levine RL
PLoS Med; 2006 Jul; 3(7):e270. PubMed ID: 16834459
[TBL] [Abstract][Full Text] [Related]
10. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
Pardanani A; Lasho T; Smith G; Burns CJ; Fantino E; Tefferi A
Leukemia; 2009 Aug; 23(8):1441-5. PubMed ID: 19295546
[TBL] [Abstract][Full Text] [Related]
11. Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera.
Mullally A; Bruedigam C; Poveromo L; Heidel FH; Purdon A; Vu T; Austin R; Heckl D; Breyfogle LJ; Kuhn CP; Kalaitzidis D; Armstrong SA; Williams DA; Hill GR; Ebert BL; Lane SW
Blood; 2013 May; 121(18):3692-702. PubMed ID: 23487027
[TBL] [Abstract][Full Text] [Related]
12. TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations.
Pardanani A; Hood J; Lasho T; Levine RL; Martin MB; Noronha G; Finke C; Mak CC; Mesa R; Zhu H; Soll R; Gilliland DG; Tefferi A
Leukemia; 2007 Aug; 21(8):1658-68. PubMed ID: 17541402
[TBL] [Abstract][Full Text] [Related]
13. The small molecule inhibitor G6 significantly reduces bone marrow fibrosis and the mutant burden in a mouse model of Jak2-mediated myelofibrosis.
Kirabo A; Park SO; Wamsley HL; Gali M; Baskin R; Reinhard MK; Zhao ZJ; Bisht KS; Keserű GM; Cogle CR; Sayeski PP
Am J Pathol; 2012 Sep; 181(3):858-65. PubMed ID: 22796437
[TBL] [Abstract][Full Text] [Related]
14. Study of two tyrosine kinase inhibitors on growth and signal transduction in polycythemia vera.
Gaikwad A; Prchal JT
Exp Hematol; 2007 Nov; 35(11):1647-56. PubMed ID: 17976517
[TBL] [Abstract][Full Text] [Related]
15. Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model.
Wernig G; Mercher T; Okabe R; Levine RL; Lee BH; Gilliland DG
Blood; 2006 Jun; 107(11):4274-81. PubMed ID: 16478879
[TBL] [Abstract][Full Text] [Related]
16. Critical requirement for Stat5 in a mouse model of polycythemia vera.
Yan D; Hutchison RE; Mohi G
Blood; 2012 Apr; 119(15):3539-49. PubMed ID: 22144185
[TBL] [Abstract][Full Text] [Related]
17. Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2
Hu M; Xu C; Yang C; Zuo H; Chen C; Zhang D; Shi G; Wang W; Shi J; Zhang T
J Exp Clin Cancer Res; 2019 Feb; 38(1):49. PubMed ID: 30717771
[TBL] [Abstract][Full Text] [Related]
18. Targeting myeloproliferative neoplasms with JAK inhibitors.
Pardanani A; Tefferi A
Curr Opin Hematol; 2011 Mar; 18(2):105-10. PubMed ID: 21245760
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.
Koppikar P; Abdel-Wahab O; Hedvat C; Marubayashi S; Patel J; Goel A; Kucine N; Gardner JR; Combs AP; Vaddi K; Haley PJ; Burn TC; Rupar M; Bromberg JF; Heaney ML; de Stanchina E; Fridman JS; Levine RL
Blood; 2010 Apr; 115(14):2919-27. PubMed ID: 20154217
[TBL] [Abstract][Full Text] [Related]
20. The Jak2 inhibitor, G6, alleviates Jak2-V617F-mediated myeloproliferative neoplasia by providing significant therapeutic efficacy to the bone marrow.
Kirabo A; Park SO; Majumder A; Gali M; Reinhard MK; Wamsley HL; Zhao ZJ; Cogle CR; Bisht KS; Keserü GM; Sayeski PP
Neoplasia; 2011 Nov; 13(11):1058-68. PubMed ID: 22131881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
